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2Abstract
High-grade serous carcinoma (HGSC) is the most common and deadliest ovarian cancer 
(OC) type, accounting for 70–80% of OC deaths. This high mortality is largely due to late 
diagnosis. Early detection is thus crucial to reduce mortality yet tumor pathogenesis of HGSC 
remains poorly understood making early detection exceedingly difficult. Faithfully and reliably 
representing the clinical nature of human HGSC, a recently-developed triple knockout (TKO) 
mouse model offers a unique opportunity to examine the entire disease spectrum of HGSC. 
Metabolic alternations were investigated by applying Ultra Performance Liquid Chromatography 
Mass Spectrometry (UPLC-MS) to serum samples collected from these mice at premalignant, 
early, and advanced stages of HGSC. This comprehensive analysis revealed a panel of 29 serum 
metabolites that distinguished mice with HGSC from controls and mice with uterine tumors with 
over 95% accuracy. Meanwhile, our panel could further distinguish early stage HGSC from 
controls with 100% accuracy, and from advanced stage HGSC with over 90% accuracy. Important 
identified metabolites included phospholipids, sphingomyelins, sterols, N-acyl taurine, 
oligopeptides, bilirubin, 2(3)-hydroxysebacic acids, uridine, N-acetylneuraminic acid, and 
pyrazine derivatives. Overall, our study provides insights into dysregulated metabolism associated 
with HGSC development and progression, and serves as a useful guide toward early detection.
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4Introduction
Ovarian cancer (OC) is the most lethal gynecologic malignancy and the seventh most 
commonly diagnosed cancer among women in the world 1. The overall 5-year survival rate of OC 
is 47% 2. Due to the lack of specific symptoms, however, ovarian cancer is frequently diagnosed 
in late stages 3, 4 where 5-year survival rates are only 29% 2. Among all the OC subtypes, high-
grade serous carcinoma (HGSC), also known as high-grade serous ovarian cancer, is the most 
common and deadliest type, accounting for 70–80% of OC deaths 2, 5, 6. The high mortality of 
HGSC is largely attributable to advanced-stage diagnosis. Approximately 80% of HGSC cases are 
diagnosed at advanced stage (stage III or IV), in which the 5-year and 10-year survival rates are 
32.1% and 15%, respectively. Though only about 20% of HGSCs are detected at early stage (stage 
I or II), the early-stage diagnosis of HGSC dramatically raises patient survival to 71.4% (5-year) 
and 53% (10-year) 6, 7. Hence, early detection of HGSC would be crucial to improving OC patients’ 
survival. Unfortunately, the cellular origin and tumor pathogenesis of HGSC still remain poorly 
understood, making early detection difficult 5, 8, 9.
Presently, no diagnostic tests are available for detecting HGSC at an early stage among at-
risk patients, let alone screening tests for asymptomatic women in the general population 6, 10-13. 
The conventional strategy for OC risk evaluation includes trans-vaginal ultrasound and 
measurement of the serum tumor biomarker cancer antigen 125 (CA125) levels. However, this 
biomarker is of limited use as serum elevations of CA125 can be observed in a number of different 
conditions unrelated to OC 14. In addition to CA125, there have been several biomarker-based tests 
approved by FDA in ovarian cancer 15. However, these FDA-approved tests are neither diagnostic 
tests nor screening tests for OC. They are merely for referral purposes after ovarian tumor 
diagnosis is established. For example, the multivariate index assay OVA1 test is applied mainly to 
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5evaluate the likelihood of malignancy in women presenting an ovarian adnexal mass prior to 
surgery 15, 16. 
Metabolomics has emerged as a promising tool for biomarker discovery leading to 
enhanced diagnostics as well as providing insight into the molecular underpinnings of disease 
biology 17.  Nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) are the 
two techniques that have been most used for profiling metabolic alterations associated with OC in 
serum 18-23, plasma 24-27, urine 28-31, tissue 32-34, and ovarian cyst fluid 35. Dysregulation in 
nucleotide, histidine, tryptophan, mucin 28, phospholipid, and piperidine metabolic pathways 24, 
fatty acid β-oxidation, and glycolysis 33 have been associated with OC development and 
progression. The majority of these new metabolic markers, however, are non-HGSC related. 
One major impediment to HGSC early detection is the lack of knowledge of early tumor 
development and progression. To better understand the pathogenesis of ovarian cancer, we 
developed two mouse models of HGSC: (1) a double-knockout (DKO) mice (Dicer1 flox/flox Pten 
flox/flox Amhr2 cre/+) by inactivating the Dicer1 and Pten genes, and (2) a triple-mutant (TKO) mice 
(p53 LSL-R172H/+ Dicer1 flox/flox Pten flox/flox Amhr2 cre/+) by adding a p53 mutation (R172H), which is 
equivalent to human p53-R175H mutant, one of the frequent p53 mutations found in human OC 
36, 37. As p53 mutations are observed in almost all human HGSC cases (96%) 38, 39, the TKO mouse 
model would be genetically closer to human HGSC than the DKO model we previously studied 
20. These mice develop metastatic HGSC that faithfully model human HGSC phenotypically, 
histopathologically, and at the molecular level 37. Remarkably, HGSC from these mice reproduces 
the clinical metastasis of human HGSC in 100% of cases. In these models, HGSC originates and 
develops progressively in the fallopian tube, envelops the ovaries, and then aggressively 
metastasizes throughout the peritoneal cavity, including the omentum, diaphragm, mesentery, and 
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6peritoneal membrane. These extensive metastases invariably induce massive ascites and inevitably 
kill the mice (100%). These mouse models therefore present a rare and unique opportunity to study 
the entire disease spectrum of HGSC—from inception to early progression to metastasis—
particularly early-stage progression.
Here, using a “deep” ultra performance liquid chromatography−mass spectrometry 
(UPLC-MS) approach, we characterize serum metabolic profiles of p53-Dicer1-Pten TKO mice 
at premalignant stage, early stage, and advanced stage of HGSC. Among the identified are 
metabolites closely associated with HGSC, which discriminate HGSC from controls and from 
uterine tumors (UT) with over 95% accuracy, sensitivity, and specificity. The same metabolite 
panel is able to further distinguish early-stage HGSC from advanced-stage HGSC with over 90% 
accuracy, sensitivity, and specificity, and distinguish early stage HGSC against control samples 
with 100% sensitivity, specificity, and accuracy, respectively. The biological relevance of the 
differential metabolites is discussed, gaining insights into disease development and progression. 
This 29-feature panel enables effective detection of early-stage as well as advanced-stage HGSCs, 
offering potential to diagnose HGSC at early stages.
Materials and Methods
Chemicals
LC-MS grade methanol, LC-MS grade isopropanol, LC-MS grade acetonitrile, LC-MS 
grade water, formic acid (99.5+%), ammonium acetate, and ammonium hydroxide were purchased 
from Fisher Chemical (Fisher Scientific International, Inc. Pittsburgh, PA, USA) and used to 
prepare mobile phases and solutions.
Mice and Serum Sampling
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7In this study, triple-mutant (TKO) mice (p53 LSL-R172H/+ Dicer1 flox/flox Pten flox/flox Amhr2 
cre/+) were generated by mating p53 LSL-R172H/+ Dicer1 flox/flox Pten flox/flox female with Dicer1 flox/flox 
Pten flox/flox Amhr2 cre/+ male mice. Serum samples were collected from TKO mice at different 
stages of tumor progression: from premalignant stage to early stage to advanced stage. Precursor 
lesions are fallopian tubes at premalignant stage, when no tumors are yet present. TKO mice with 
precursor (i.e. premalignant stage) lesions in the fallopian tubes are referred to as “TKO-Pre”; 
TKO-ET (early tumor) are TKO mice with early-stage tumors in the fallopian tube without 
evidence of metastasis; TKO-AT (advanced-stage tumor) are TKO mice with ovarian and 
peritoneal metastases accompanied by ascites; and TKO-ctrl are control mice (p53 LSL-R172H/+ 
Dicer1 flox/flox Pten flox/flox), which have the same genetic background as TKO mice but develop no 
tumors. All TKO mice developed high-grade serous carcinoma (HGSC, i.e. high-grade serous 
ovarian cancer). To enhance the selectivity for HGSC-specific metabolite markers, a tumor control 
group was also included. These were uterine tumor (UT) mice (p53 LSL-R172H/+ Pten flox/flox Amhr2 
cre/+) that developed uterine tumors, but no HGSC.
Blood samples were collected via retro-orbital bleeding after anesthesia, from 22 TKO-Pre 
mice (average age, 2.0m; age range, 1.3–3.1), 10 TKO-ET mice (4.8m: 2.5–5.9), 16 TKO-AT mice 
(6.4m: 4.3–10.1), 19 TKO-ctrl mice (3.0m: 3.0–8.2), and 17 UT mice (5.4m: 3.7–6.8). Blood 
samples were centrifuged at 14,000 rpm for 5 minutes at room temperature, and serum was 
collected and stored at -80 °C until UPLC-MS analysis. 
Sample Preparation 
Serum samples were thawed on ice and subject to two different sample preparation 
protocols to obtain profiles of both non-polar and polar sub-metabolomes. Reverse phase (RP) and 
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8hydrophilic interaction liquid chromatography (HILIC) UPLC-MS analysis in both positive and 
negative ion modes were combined for these different polarity metabolite fractions to obtain 
complementary and “deeper’ metabolome information. Methanol (for polar) or iso-propanol (for 
non-polar) was added to a 50 μL serum sample in a 3:1 ratio to precipitate proteins. Samples were 
vortex mixed for 10 s and centrifuged at 13,000 rpm for 7 min. Then, 150 μL supernatant was 
frozen at -80 °C for UPLC-MS analysis. A sample blank was prepared with 50 μL of LC-MS grade 
water, and a pooled quality control (QC) sample was created by mixing 10 μL aliquot of each 
serum sample. Both the sample blank and the pooled sample were processed with the same 
procedure as the murine serum samples. Samples were run in randomized order on consecutive 
days. Solvent blanks and sample blanks were analyzed together with murine serum samples. QC 
samples were analyzed every 12 runs to assess UPLC-MS system stability, and were used to 
compensate for time-dependent batch effects with a QC-based regression curve for each detected 
compound. 
UPLC-MS Analysis
Chromatography was performed with an Ultimate 3000 UPLC (Thermo Fisher Scientific, 
Inc., Waltham, MA, USA) system equipped with a Waters ACQUITY UPLC BEH C18, 2.1mm x 
50mm, 1.7 μm particle column or a Waters ACQUITY UPLC BEH HILIC, 2.1mm x 75mm, 1.7 
μm particle column.  A Q Exactive HF Orbitrap mass spectrometer (Thermo Fisher Scientific, Inc., 
Waltham, MA, USA) was used in all cases. For reverse phase (RP) separations, mobile phase A 
was water/acetonitrile (40:60 v/v), and mobile phase B was acetonitrile/isopropanol (10:90 v/v). 
Both mobile phases included 10 mM ammonium formate and 0.1% formic acid additives to 
improve peak shape and ionization efficiency. For hydrophilic interaction chromatography (HILIC) 
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9separations, mobile phase A was water/acetonitrile (95:5 v/v), 10 mM ammonium acetate and 0.05 
% ammonium hydroxide. Mobile phase B was acetonitrile with 0.05 % ammonium hydroxide. 
Chromatographic gradients are described in Table S1. The column temperature was 55 °C, while 
samples were maintained at 5 °C in the autosampler. Injection volumes of 5 μL and 2 μL were 
used in RP and HILIC methods, respectively. RP and HILIC chromatography were performed both 
in positive and negative ion modes, MS parameters can be found in supplemental information 
(Table S2).
For metabolite identification purposes, top 5 data dependent acquisition (DDA) 
experiments were used to collect MS/MS spectra using stepped normalized collision energy (NCE) 
of 10, 30 and 50 V.  For compounds missed by DDA, parallel reaction monitoring (PRM) 
experiments were performed at collision energies ranging from 10 V to 40 V to obtain 
fragmentation data for identification purposes.
Data Processing
Spectral features were extracted from the raw data using Compound Discoverer v2.1 
software (Thermo Fisher Scientific, Inc., Waltham, MA, USA). This procedure included 
chromatographic alignment, peak picking, peak area integration and QC-based compound area 
normalization. Features that eluted with the chromatographic solvent front with retention times < 
0.5 min in RP datasets and < 0.9 min in HILIC datasets were considered unreliable due to potential 
ion suppression effects 40 and were thus removed. Further filtering was carried out by removing 
features that were not present in 50 % of at least one of the serum sample groups at ten times the 
baseline abundance, defined as the peak area of the sample blank run. Welch’s t-test with a 
Benjamini Hochberg correction was applied to TKO vs. TKO-ctrl mouse groups, and TKO vs. UT 
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10
mouse groups. The union of differential features from both control and UT comparisons were 
chosen for down-selecting HGSC-specific features. The most useful set of features for 
classification were produced with genetic algorithms41 (GAs, MATLAB R2016a, The 
MathWorks, Natick, MA with PLS_Toolbox v.8.1.1, Eigenvector Research, Wenatchee, WA). 
GAs are evolutionary algorithms that generates solutions to optimization problems. They have 
been widely used in feature selection due to their high performance in large-scale feature selection 
rate and classification accuracy 41. Parameters for GA variable selection are provided in the 
supplemental information (Table S3). After the GA variable selection process, features were 
chosen based on frequency criteria. Principal component analysis (PCA) and orthogonal Partial 
Least Square Discriminant Analysis (oPLS-DA) 42 were performed to assess the discriminating 
power of metabolite datasets in non-supervised and supervised manners, respectively. Data were 
preprocessed by autoscaling prior to PCA and oPLS-DA analysis, and cross-validated using 10 
iterations of random sample subsets. Data generated in this work are available through the NIH 
Metabolomics Workbench (http://www.metabolomicsworkbench.org/) with project ID PR000784 
(doi: 10.21228/M8BH6F, study ID ST001172).
Discriminant Feature Identification
Metabolite identification was attempted for the panel of best discriminant features. Mass 
spectral ion adduct analysis was first performed to ensure the unambiguous assignment of the 
feature of interest in each mass spectrum. Elemental formulas were then generated based on exact 
masses with a maximum mass error of 10 mDa and isotopic patterns using Compound Discoverer 
v2.1. The elements included in the elemental formula search were constrained to C, H, N, O, P, 
and S. Tentative identities were searched against the human metabolome database (HMDB) 43, 
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11
Lipid Maps database 44 and Metlin database 45 using both the accurate mass and generated 
elemental formulae with a mass error of 10 mDa. Tandem MS databases such as Metlin, mzCloud 
46, and MassBank 47 were used together with literature searches to further confirm the identity of 
the metabolite candidates for which tandem MS/MS data were successfully acquired. 
Fragmentation patterns were also manually analyzed in a few cases to distinguish between 
different isobaric species.
Results and Discussion
Multivariate Classification Performance 
A dataset comprising a total of 5937 spectral features that were above background and 
chromatographically retained was produced by combining the RP ESI(+), RP ESI(-), HILIC 
ESI(+), and HILIC ESI(-) datasets. Initially, the extent by which UPLC−MS metabolic profiling 
could differentiate serum of 19 TKO-Pre, 10 TKO-ET and 16 TKO-AT mice, against 22 TKO-ctrl 
and 17 UT mice was investigated. An unsupervised PCA exploration of these datasets showed 
large overlap between TKO-Pre and TKO-Ctrl mice (Figure 1), indicating that, as expected, only 
subtle differences exist between the two groups because TKO-Pre mice had not yet developed any 
tumors and were phenotypically closer to the healthy controls. Thus, for the following data 
analysis, the TKO mouse group was combined by TKO-ET and AT mice. 
The set of 5937 features was utilized to build an oPLS-DA model that distinguished serum 
samples from TKO mice against TKO-Ctrl and UT mice. Performance characteristics of this model 
(Figure 2A,B) were 88.1, 92.8, and 90.4% for the cross-validated sensitivity, specificity, and 
accuracy, respectively. Five serum samples were systematically misclassified, including two 
TKO-ET mice with ID No.42 and 51, one TKO-AT mouse labeled No.62, and two UT mice 
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labeled No.69 and 78. Sample cohort information can be found in the supplemental information. 
The model employed a total of four latent variables and interpreted 42.1% and 54.48% variance 
from the X (feature peak area) and Y (sample class membership) blocks, respectively. Although 
this model’s performance was acceptable, GA feature selection was used to obtain a smaller, more 
robust, metabolic feature set that could better discriminate TKO mice against TKO-Ctrl and UT 
mice. GA variable selection led to a 29-feature panel (Figure 2 C,D) with 96.2, 97.2, and 96.7% 
cross-validated sensitivity, specificity and accuracy, respectively. In this case, only two serum 
samples were systematically misclassified. The two misclassified samples were collected from a 
TKO-ET mouse labeled No.42 and a UT mouse labeled No.68. The TKO-ET mouse was 
repeatedly misclassified as a TKO-Ctrl mouse. This could be due to the age of the mouse, 2.5m 
when sample was collected, was much younger than the rest of the TKO-ET mice (average age: 
4.8m) and close to the average age of the TKO-Pre mice (average age: 2.0m). As TKO-Pre mice 
were phenotypically closer to the TKO-Ctrl mice, this may explain why the young TKO-ET mouse 
was classified as a TKO-Ctrl mouse in the models. The three latent variable model interpreted 
58.7% and 56.1% variance from the X and Y blocks, respectively. Binary comparisons (TKO vs. 
TKO-Ctrl, TKO vs. UT) were also performed (Figure 3 A,B), indicating that the 29-feature panel 
was strongly HGSC-specific and could differentiate TKO mice from control and UT mice with 
high performance at the same time. In these cases, the classification accuracy ranged from 95.3 – 
98.1%, with cross-validated sensitivity of 96.2 – 96.5% and specificity of 94.1 – 100%. PCA was 
utilized to further evaluate the discriminant performance of the 29-feature panel in an unsupervised 
manner and rule out any overfitting. Score plots were generated for both the initial 5937-feature 
set and the selected 29-feature panel (Figure S1). Good group clustering and increased variance 
captured were observed with the 29-feature panel, even in an unsupervised fashion. 
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As accurate staging and early-stage disease detection greatly improves clinical outcome, 
we investigated the performance of the 29-feature panel in discriminating early- and late-stages of 
HGSC. This panel of 29 metabolites distinguished TKO-ET from TKO-AT mice with 90.0%, 
93.8%, and 91.9% for the cross-validated sensitivity, specificity, and accuracy, respectively 
(Figure 3 C). Permutation tests with 2,000 iterations returned p-value of 0.017 measured using 
group separation distance 48, avoided overfitting and further validated the model. We further 
explored the potential of the 29-feature panel in disease early detection. The oPLS-DA model 
successfully discriminated TKO-ET against TKO-Ctrl mice with 100% cross-validated sensitivity, 
specificity, and accuracy, respectively. This panel, however, was indistinguishable between 
precursors and controls. We used the 22 precursor (TKO-Pre) samples as an unknown sample set 
and input into this classification model, 18 out of 22 TKO-Pre samples were predicted as being 
similar to TKO-Ctrl samples (Figure 4), echoing our previous statement that the TKO-Pre mice 
were phenotypically closer to the TKO-Ctrl mice. Nevertheless, this 29-feature panel enabled 
effective detection of early-stage as well as advanced-stage HGSCs, offering potential to diagnose 
HGSC at early stage. 
Discriminant Metabolite Identification
Following multivariate analysis, metabolite identification was carried out for the species 
in the 29-feature panel. Twenty-four of the 29 metabolic features were identified by both high 
resolution MS and MS/MS (Table 1). Table S4 provides detailed MS/MS fragmentation 
information and confidence level for each identified species. Metabolites in the panel included 
lipids, oligopeptides, and other small molecules such as bilirubin, uridine, hydroxysebacic acids, 
and N-acetylneuraminic acid (NeuAc). For features that did not yield informative MS/MS 
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information, tentative assignments were made based on high-resolution MS and isotopic relative 
ion abundances only (Table 1, italicized), and should be considered tentative until further research 
is pursued. 
HGSC-Related Metabolic Alternations
Understanding the biological role of specific metabolites is also crucial to enhance our 
understanding of HGSC metabolism. Discussed below is the potential role of the differential 
metabolites that were altered in different HGSC stages (Ctrl, Pre, ET and AT). The biological roles 
of the rest identified metabolites can be found in the supplemental information. 
Alterations in metabolism of phosphatidylcholine (PC) and its ester-bond hydrolysis 
product, lysophosphatidylcholine (LysoPC), have been reported in several gynecological cancers, 
including ovarian cancer studies 49-53, cervical cancer 54, and breast cancer 55. Our findings of 
decreased PC(P-40:6) (Table 1; fold change: -0.36) and elevated LysoPC(20:0) (Table 1; fold 
change: +0.93) serum levels in TKO-AT mice are in agreement with published work of ovarian 
cancer studies 51, 53. The alternations are likely due to the activation of PC-cycle enzymes, 
including choline kinase (ChoK) and PC-specific phospholipase C (PC-plc) 50, 56. Moreover, the 
significantly decreased PC and elevated LysoPC alternations were found in advanced-stage 
(Figure 5), suggesting these changes were related to tumor metastasis and progression. This 
observation awaits further validation and investigation. 
Cardiolipins (CLs) are a unique mitochondrial phospholipid class that regulates 
bioenergetic processes and signaling events related to apoptosis and aging 57, 58. An increase of 
CL(67:2) serum levels in TKO-ET mice was observed (Figure 5). However, further studies are 
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still needed to understand the role of CL in cellular function and signaling pathways as they relate 
to ovarian cancer. 
One of the identified features in the 29-metabolite panel was the sphingomyelin (SM) 
SM(d32:1) (Table 1). SM is an essential element of plasma membrane structure and plays 
important roles in cancer biology, with the hydrolysis by sphingomyelinases resulting in the 
formation of ceramides, key players in cellular proliferation, growth and apoptosis 59, 60. 
Consequently, changes in SM levels can have a profound effect on the biophysical properties of 
cellular membranes and signaling 61. We observed decreased levels of SM(d32:1) in HGSC mice, 
especially in advanced-stage (Table 1; Figure 5; fold change: -1.75). Along the same lines, Braicu 
et al. have detected a decrease of SM levels in serum samples from ovarian cancer patients 62, 
strengthening the findings of our study.
Sterol metabolites derived from the cholesterol biosynthetic pathway are important 
structural components of cell membranes 63. They regulate membrane fluidity and permeability as 
well as biological activities, including lipid synthesis, cell growth and apoptosis 64. One 
discriminant feature was identified as a sterol metabolite: cholesteryl ester (CE(20:5)). CEs are 
formed by the esterification of cholesterol with long-chain fatty acids and are transported through 
the blood by lipoproteins. Over-expression of CEs has been reported in multiple malignant tumors 
65, including ovarian cancer 66. We observed a significant increase in serum level of CE(20:5) in 
TKO-AT mice (Table 1; Figure 5; fold change: +1.26), which is line with these findings. Another 
cholesterol derivative C27H43O [7-Dehydrodesmosterol, 5a-Cholesta-8,24-dien-3-one, or 
Cholesta-4,6-dien-3-one] was identified in our 29-feature panel. Gradually decreased serum level 
of 7-Dehydrodesmosterol (and/or its isomers) was detected in TKO with different stages (Table 1; 
Figure 5; fold change: -1.06). 7-Dehydrodesmosterol (and/or its isomers) is an intermediate in the 
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cholesterol biosynthesis pathway. The decrease can be attributed to the enhanced biosynthesis 
activity of cholesterol, as increased serum cholesterol level is associated with ovarian cancer 67.
N-acyl taurines (NATs) are molecules with fatty acids conjugated to taurine. We observed 
decreased serum levels of NAT(30:1) in HGSC mice, especially in advanced-stage (Table 1; 
Figure 5; fold change: -0.84). Limited research has been reported on this species, and their 
biological role remains largely unexplored. In support of our findings, Chatzakos et al. found that 
NAT reduced proliferation in human prostate cancer cells 68. Therefore, one likely explanation is 
the diminished anti-proliferative effect with decreased levels of NAT, resulting in further disease 
progression. 
A tripeptide (Glu-His-Leu or Glu-His-Ile) was found to be higher in TKO-ET mice (Table 
1; Figure 5; fold change: +0.80). Literature searches revealed no known roles for small peptides in 
ovarian cancer. Some proteases such as protease M, however, have been reported to be 
overexpressed in serum of ovarian cancer patients 69-72, and could therefore increase the levels of 
small circulating peptides in HGSC. 
Bilirubin, the end product of heme catabolism in mammals, exhibits antioxidant properties 
by scavenging peroxyl radicals 73, 74. Increased serum bilirubin concentration has been found to be 
associated with decreased risk for cancer mortality 75. We observed decreased serum levels of 
bilirubin in HGSC mice, with further decrease in advanced-stage (Table 1; Figure 5; fold change: 
[M-H]-: -0.88). This finding agrees with previous work by our group, showing lowered 
concentration of bilirubin for early-stage ovarian cancer in Dicer-Pten double-knockout (DKO) 
mice compared with controls 20. One likely explanation of this finding is the diminished protection 
of bilirubin against oxidative stress in ovarian cancer, leading to further disease progression. 
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Two (3)-hydroxysebacic acids have been found to be important diagnostic markers for 
impaired peroxisomal fatty acid oxidation disorders 76. Their levels are regulated by medium chain 
acyl-CoA dehydrogenase in the fatty acid β-oxidation pathway. Increased excretion of 2 (3)-
hydroxysebacic acids is associated with acyl-CoA dehydrogenase deficiency and decreased β-
oxidation of fatty acids 76-78. Our experiments reported lower serum levels of 2 (3)-hydroxysebacic 
acids in TKO-AT mice (Table 1; Figure 5; fold change: -0.90), suggesting increased activity of 
acyl-CoA dehydrogenase and fatty acid β-oxidation. In support of this hypothesis, both Fong et al. 
and Ke et al. have observed increased fatty acid β-oxidation in ovarian cancer patients 24, 33.
We observed significantly decreased serum levels of uridine in HGSC mice, especially in 
early-stage (Table 1, Figure 5; fold change: -2.21). The level of circulating uridine is a reflection 
of de novo pyrimidine biosynthesis and the utilization of uridine by tissue via the salvage pathway 
79. As cell proliferation in tumors requires a large pool of pyrimidines for rapid DNA and RNA 
synthesis, the observed relative decrease in serum uridine levels could be due to either tissue 
uridine uptake or rapid uridine catabolism in ovarian cancer. 
N-Acetylneuraminic acid (NeuAc), also known as sialic acid (SA), is a major constituent 
of glycoproteins and glycolipids 80. We observed significantly increased serum NeuAc levels in 
TKO-AT mice (Table 1, Figure 5, fold change: 0.94). In agreement with this finding, increased 
SA serum levels have been reported in ovarian cancer patients compared to healthy controls 81, 82. 
This elevation of NeuAc serum levels could be attributed to high levels of glycoprotein and 
glycolipid release due to the high turnover of malignant tumor cells 80, 83. Moreover, the detected 
elevation of NeuAc levels in TKO-AT mice suggests its strong association with disease 
progression, confirming its potential application as a diagnostic indicator for HGSC malignancy 
81, 84, 85. 
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One feature in the discriminant metabolite panel was identified as a C6H8N2, likely a 
pyrazine derivative, with lower abundance in TKO-AT mice (Table 1; Figure 5; fold change: -
0.19). Many pyrazines are exogenous metabolites that originate from food sources, such as cereals, 
soybeans, potatoes, cocoa products and other natural products 86, and have been reported to exhibit 
anticancer activities 87. Although all mice in this study were fed the same diet, it is plausible that 
altered metabolism in HGSC mice led to differences in abundance of dietary metabolites following 
disease progression. 
Conclusions
Serum from TKO p53-Dicer1-Pten mice with both early- and advanced-stage HGSC 
tumors was successfully profiled using a UPLC-MS-based non-targeted metabolomics strategy. 
Identified are a panel of 29 metabolites that distinguishes TKO mice from TKO-Ctrl and UT mice, 
and further distinguishes TKO-ET from TKO-AT and TKO-Ctrl. Metabolic alterations in TKO 
mice, mainly characterized by aggressive fatty acid β-oxidation, abnormal metabolism in 
phospholipids, glycoproteins and glycolipids, heme catabolism, cholesterol biosynthesis and 
pyrimidine biosynthesis, were found to be associated with HGSC development and progression. 
Identified biomarkers that differentially expressed in HGSC early- and late-stages were 
phospholipids, sphingomyelin, sterol, N-acyl taurine, oligopeptide, and other small molecules 
including bilirubin, 2(3)-hydroxysebacic acids, uridine, N-acetylneuraminic acid, and pyrazine 
derivatives. Taken together, our deep metabolomics study provided insights into dysregulated 
metabolism in HGSC, which could aid in disease diagnosis, as well as support our understanding 
of disease development and progression. In particular, this panel of 29 metabolites will serve as a 
useful guide toward early detection of high-grade serous ovarian cancer. 
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Supporting Information
Multi-group and binary PCA score plots of TKO, TKO-Ctrl and UT samples using initial 5937-
feature set and the 29-feature panel (Figure S1).
Box plots showing changes of the 29 selected spectral features in TKO-Ctrl, TKO-ET, TKO-AT 
and UT samples (Figure S2). 
Liquid chromatography gradients for RP and HILIC separation methods (Table S1).
MS acquisition parameters (Table S2).
GA variable selection parameters (Table S3).
Detailed MS/MS annotation of the 29-feature panel (Table S4). 
Sample cohort information (Table S5)
Biological roles of identified features not discussed in main manuscript. 
Figure Captions
Figure 1. PCA score plot including all sample groups using the total initial set of 5937 spectral 
features. The clustering of samples in this plot reveals clear separation between TKO-ET mice 
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from TKO-AT mice and UT mice, a moderate separation between TKO-ET mice and TKO-Ctrl 
mice with some overlap, and complete overlap of TKO-Pre and TKO-Ctrl mice. Pooled QC 
samples, represented by orange stars, clustered towards the center of the plot, indicating technical 
variance was minimal. 
Figure 2. (A) oPLS-DA score plot depicting clustering of samples using the initial set of 5937 
spectral features. (B) oPLS-DA cross-validated classification plot using 5937 spectral features. 
The X-axis represents randomized sample number, and y-axis represents the cross-validated 
predicted scores of the oPLS-DA classification model. (C) oPLS-DA scores plot using the GA-
selected 29-feature panel. (D) oPLS-DA cross-validated classification plot using the 29-feature 
panel. TKO, TKO-Ctrl and UT samples are represented by black squares, red circles and blue 
triangles, respectively. The threshold for sample classification is represented by the green dashed 
line. Cross-validated sensitivity, specificity and accuracy values are given for each model. TKO 
samples are a combination of TKO-ET and TKO-AT samples.
Figure 3. oPLS-DA scores plot depicting clustering of samples between (A) TKO and TKO-Ctrl 
samples, (B) TKO and UT samples, and (C) TKO-ET and TKO-AT samples using the 29-feature 
panel. Variance between classes is captured across the X-axis. TKO, TKO-Ctrl, UT, TKO-ET and 
TKO-AT samples are represented by black squares, red circles, blue triangles, green diamonds and 
pink triangles, respectively. The threshold for sample classification is represented by the green 
dashed line. Cross-validated sensitivity, specificity and accuracy values are given for each model. 
TKO samples are combined with TKO-ET and TKO-AT samples. 
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Figure 4. oPLS-DA cross-validated classification plot between ET and Ctrl samples using the 29-
feature panel. The X-axis represents the randomized sample number, and y-axis represents the 
cross-validated predicted scores of the binary oPLS-DA classification model. ET and Ctrl samples 
are represented by green diamonds and red circles, respectively. Precursor (Pre) samples projected 
into the model are represented by orange triangles. The threshold for sample classification is 
represented by the green dashed line. Cross-validated sensitivity, specificity and accuracy values 
are given for the model.
Figure 5. Box plots showing changes of the selected identified metabolites in Ctrl (n=19), Pre 
(n=22), ET (n=10) and AT (n=16) samples. The mean, median, upper and lower quartiles, outliers, 
and minimum and maximum (whiskers) values are displayed. *Features have isomers. 
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Table 1. Annotation of metabolites in the 29-feature panel. Acquisition mode, retention time, 
observed exact mass and mass error, theoretical mass, predicted elemental formula, observed 
adduct, p-value of abundances between TKO and TKO-Ctrl samples, and between TKO and UT 
samples, and fold changes (FC, calculated as the base 2 logarithm of the average abundance ratios 
between TKO and TKO-Ctrl samples) are included. Positive FC values indicate increased 
abundance in TKO samples, while negative values indicate higher abundance in TKO-Ctrl samples. 
All p-values are calculated using an FDR-corrected t-test. For additional fragmentation 
information and level of confidence for each identification, please refer to Table S4. Abbreviations: 
Glu: Glutamic acid; His: Histidine; Leu: Leucine; Ile: Isoleucine; CE: cholesteryl ester; PC: 
phosphatidylcholine; CL: cardiolipin; NAT: N-acyl taurine; SM: sphingomyelin; PS: 
phosphatidylserine; NeuAc: N-Acetylneuraminic acid. 
Page 22 of 35
ACS Paragon Plus Environment
Journal of Proteome Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
23
Feature 
No.
Acquisition 
Mode
Retention 
Time (min)
Experimental 
m/z
Theoretical 
m/z
Elemental 
Formula
Adduct 
Type
Mass Error 
(ppm)
Fold 
Change
p-value 
HGSC vs. control / 
HGSC vs. UT
Metabolite Identity
208 HILIC ESI+ 4.96 109.0765 109.0760 C6H8N2 [M+H]+ 4.58 -0.19 0.00347 / 8.45e-7
Dimethypyrazine
Ethylpyrazine 
2-Picolylamine
202 HILIC ESI+ 2.67 271.1151 271.1149 C9H14N6O4 [M+H]+ 0.74 1.08 0.000261 / 1.52e-6 --
385 HILIC ESI- 1.65 516.7524 -- -- [M+Br]- -- 0.68 0.00116 / 2.86e-6 --
277 RP ESI- 1.02 583.2576 583.2562 C33H36N4O6 [M-H]- 2.40 -0.88 1.10e-7 / 5.57e-6 Bilirubin
494 HILIC ESI- 1.58 514.7545 -- -- [M+Br]- -- 1.33 0.000762 / 2.51e-5 --
363 HILIC ESI+ 2.21 398.2022 398.2034 C17H27N5O6 [M+H]+ -3.01 0.80 0.00148 / 3.13e-5
Glu-His-Leu 
Glu-His-Ile
427 RP ESI+ 8.15 693.5567 693.5581 C47H74O2 [M+Na]+ -2.02 1.26 0.00104 / 0.000112 CE(20:5)
303 RP ESI+ 1.42 552.4015 552.4024 C28H58NO7P [M+H]+ -1.63 0.93 0.00546 / 0.000114 LysoPC(20:0)
751 HILIC ESI+ 1.28 696.4993 696.5012 C76H144O17P2 [M+2H]2+ -2.73 0.57 0.0116 / 0.000124 CL(67:2)
37 HILIC ESI- 2.20 217.1075 217.1081 C10H18O5 [M-H]- -2.76 -0.42 0.00697 / 0.000137 2(3)-Hydroxysebacic acid
572 HILIC ESI+ 4.56 454.8905 -- -- [M+H]+ -- -1.50 9.44e-7 / 0.000149 --
651 HILIC ESI- 1.27 281.0358 281.0360 C9H12N2O6 [M+Cl]- -0.71 -0.22 0.00934 / 0.000351 Uridine (isotopic peak)
557 HILIC ESI- 3.22 308.0988 308.0987 C11H19NO9 [M-H]- 0.32 0.94 0.00316 / 0.000360 NeuAc
88 RP ESI+ 1.22 607.2522 607.2527 C33H36N4O6 [M+Na]+ -0.82 -1.10 1.34e-6 / 0.000491 Bilirubin
274 RP ESI+ 1.25 540.4465 540.4445 C32H63NO4S [M+H-H2O]+ 3.70 -0.84 3.19e-6 / 0.000718 NAT(30:1)
696 HILIC ESI- 1.27 279.0387 279.0389 C9H12N2O6 [M+Cl]- -0.72 -2.21 9.20e-14 / 0.000865 Uridine
449 RP ESI- 6.88 673.5272 673.5290 C37H75N2O6P [M-H]- -2.67 -1.75 0.000209 / 0.00121 SM(d32:1)
189 RP ESI+ 1.20 585.2700 585.2708 C33H36N4O6 [M+H]+ -1.37 -0.21 0.0161 / 0.00152 Bilirubin
210 HILIC ESI+ 4.31 619.1976 -- -- [M+H]+ -- 0.18 0.00958 / 0.00214 --
98 HILIC ESI- 2.68 247.1184 247.1187 C11H20O6 [M-H]- -1.21 -1.98 3.57e-10 / 0.00237 Fatty acyl glucoside
191 RP ESI+ 4.47 818.6049 818.6058 C48H84NO7P [M+H]+ -1.10 -0.36 0.0145 / 0.00384 PC(P-40:6)
485 RP ESI+ 6.27 978.7103 978.7158 C56H100NO10P [M+H]+ -5.62 0.16 0.000306 / 0.00413
PS(50:5)
PS(O-50:6(OH))
PS(P-50:5(OH)) 
700 RP ESI- 1.06 472.1559 472.1586 C20H23N7O7 [M-H]- -5.72 0.75 0.00116 / 0.00680
Folinic acid
10-Formyltetrahydrofolate
Pteroyl-D-glutamic acid
22 RP ESI- 3.70 491.3419 491.3412 C26H52O6S [M-H]- 1.42 3.03 0.00225 / 0.00711 Fatty acid ester derivatives
644 HILIC ESI+ 3.93 276.1190 276.1190 C10H17N3O6 [M+H]+ 0.00 2.93 0.00293 / 0.00867
Norophthalmic acid
Gamma-Glutamyl Glutamine
725 HILIC ESI- 1.25 219.0187 219.0193 C5H8N4O4S [M-H]- -2.74 -0.29 0.0120 / 0.00890 Taurine derivatives
48 RP ESI- 0.93 462.0594 462.0616 C14H25NO11 [M+Br]- -4.76 2.78 0.00269 / 0.00963
N-Acetyllactosamine
Beta-1,4-mannose-N-
acetylglucosamine
Lacto-N-biose I
772 HILIC ESI- 3.61 217.1075 217.1081 C10H18O5 [M-H]- -2.76 -0.90 0.00114 / 0.0117 2(3)-Hydroxysebacic acid
29 RP ESI+ 3.27 383.3306 383.3308 C27H42O [M+H]+ -0.52 -1.06 1.25e-9 / 0.0127
7-Dehydrodesmosterol
5a-Cholesta-8,24-dien-3-one
Cholesta-4,6-dien-3-one
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Figure 1.
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Figure 2.
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Figure 3.
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Figure 4.
Page 27 of 35
ACS Paragon Plus Environment
Journal of Proteome Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
28
Figure 5.
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